Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Dupixent
Dupixent
AstraZeneca and Amgen quietly admit tezepelumab defeat as the Dupixent challenger heads to FDA
Endpoints
Thu, 07/29/21 - 11:10 am
AstraZeneca
Amgen
tezepelumab
asthma
Dupixent
Sanofi
Sanofi and Regeneron's high-flying Dupixent tops May pharma TV spending, trading places with AbbVie's Humira
Fierce Pharma
Thu, 06/17/21 - 12:12 pm
Sanofi
Regeneron
Dupixent
DTC ads
television ads
Sanofi, touting new data, sees 'best-in-class' case for Dupixent in pediatric asthma
Fierce Pharma
Mon, 05/17/21 - 10:46 am
Sanofi
Dupixent
asthma
pediatric
Pharma TV Ad Spending Trends: Companies in the Top Ten this Week
Xtalks
Thu, 05/13/21 - 11:46 pm
DTC ads
television ads
Dupixent
Trulicity
Rybelsus
Amgen, AstraZeneca's tezepelumab is looking for a slice of blockbuster asthma market dominated by Sanofi's Dupixent
Fierce Biotech
Thu, 05/13/21 - 10:57 am
Amgen
AstraZeneca
tezepelumab
asthma
severe asthma
Sanofi
Dupixent
FDA
AbbVie's Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along
Fierce Pharma
Wed, 05/5/21 - 10:50 am
AbbVie
Humira
DTC advertising
television ads
Sanofi
Dupixent
Novo Nordisk
Rybelsus
FDA hits Leo Pharma with a CRL for what the biotech says are questions about the 'device component' of eczema candidate
Endpoints
Fri, 04/30/21 - 10:43 am
LEO Pharma
FDA
atopic dermatitis
eczema
monoclonal antibodies
Dupixent
Sanofi reports sales growth amid Dupixent's China launch, but reveals PDUFA delay in Pompe disease program
Endpoints
Wed, 04/28/21 - 10:30 am
Sanofi
earnings
China
Dupixent
Pompe disease
Sanofi teams with virtual reality biotech on oral Dupixent successor
Endpoints
Mon, 04/12/21 - 10:42 am
Sanofi
Dupixent
C4X Discovery
small molecule drugs
Regeneron has a winner in Dupixent and big sales hopes. So why are so few patients taking it?
Endpoints
Mon, 02/8/21 - 10:25 am
Dupixent
Regeneron
Sanofi
eczema
Pfizer, still chasing Dupixent, releases fifth round of data for eczema JAK inhibitor abrocitinib
Endpoints
Wed, 11/11/20 - 11:04 am
Pfizer
JAK inhibitors
abrocitinib
Dupixent
atopic dermatitis
clinical trials
Sanofi, despite COVID-19, sees early gains from CEO Hudson's strategy revamp
Fierce Pharma
Thu, 10/29/20 - 12:19 pm
Sanofi
earnings
Dupixent
Paul Hudson
Pharma CEOs
Sanofi, Regeneron chase 4th Dupixent approval with rare esophageal disease data
Fierce Pharma
Mon, 10/26/20 - 11:04 pm
Sanofi
Regeneron
FDA
Dupixent
eosinophilic esophagitis
Dupixent Posts Positive Results in Phase III Pediatric Asthma Study
BioSpace
Tue, 10/13/20 - 11:06 am
Regeneron
Sanofi
pediatric
asthma
clinical trials
Dupixent
Sanofi, Regeneron get FDA breakthrough therapy status for Dupixent to treat eosinophilic esophagitis
Pharmaceutical Business Review
Mon, 09/14/20 - 10:50 am
Sanofi
Regeneron
Dupixent
FDA
eosinophilic esophagitis
breakthrough status
Can Sanofi's top drug carry it through a pandemic?
BioPharma Dive
Wed, 07/29/20 - 01:16 pm
Sanofi
Dupixent
earnings
pandemic
COVID-19
Leo Pharma offloads a psoriasis asset as their Dupixent rival heads to the FDA
Endpoints
Tue, 07/21/20 - 10:27 am
LEO Pharma
psoriasis
Sanofi
Dupixent
LP0058
LEO eyeing 2021 US launch for eczema drug tralokinumab
Pharmaforum
Fri, 07/10/20 - 10:47 am
LEO Pharma
eczema
tralokinumab
Sanofi
Dupixent
Sanofi, Regeneron Win China Approval For Dupixent Dermatitis Drug
Yahoo/SmarterAnalyst
Mon, 06/22/20 - 10:30 am
Sanofi
Regeneron
China
Dupixent
atopic dermatitis
New safety data expose potential weakness as Pfizer's abrocitinib takes on Dupixent in eczema
Endpoints
Thu, 06/4/20 - 11:15 am
Pfizer
abrocitinib
Dupixent
clinical trials
eczema
Pages
« first
‹ previous
1
2
3
4
5
6
7
next ›
last »